Seres Therapeutics CEO Eric Shaff sells shares worth 1,354
MCRB Stock | USD 0.91 0.07 8.33% |
About 54% of Seres Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Seres Therapeutics suggests that some traders are interested. The current market sentiment, together with Seres Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Seres Therapeutics stock news signals to limit their universe of possible portfolio assets.
Seres |
Seres Therapeutics CEO Eric Shaff sells shares worth 1,354
Read at investing.com
Seres Therapeutics Fundamental Analysis
We analyze Seres Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seres Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seres Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Seres Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Seres Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Seres Therapeutics stock to make a market-neutral strategy. Peer analysis of Seres Therapeutics could also be used in its relative valuation, which is a method of valuing Seres Therapeutics by comparing valuation metrics with similar companies.
Peers
Seres Therapeutics Related Equities
FATE | Fate Therapeutics | 3.89 | ||||
VCYT | Veracyte | 3.58 | ||||
IOVA | Iovance Biotherapeutics | 2.22 | ||||
SYRS | Syros Pharmaceuticals | 9.38 |
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |